Novel 64cu(Ii) Radiotracer For Diagnostic Of Hypoxia
![](https://birad.biz/wp-content/uploads/2021/04/The-Problem-15.png)
The Problem
The development of a biomarker for hypoxic tissues is essential both for diagnostic formulation and treatment planning for most cancer patients.
Although the current PET radiotracers are non-invasive imaging modality techniques of tumor hypoxia, they are not being used routinely due to slow uptake by hypoxic.
Cu(II)-tracers have been suggested to become one of the most promising PET agents for hypoxia imaging. However, one of the main drawback of Cu(II)-ATSM compounds is that they can also dissociate Cu(II) in normal and hypoxia cell, causing to chelation of Cu(II) by SOD and cytochrome C, and other rich proteins causing to:
- Unwanted cellular reactions resulting in toxicity
- Low signal to background ratio of the radiotracer
- Specificity problems
![](https://birad.biz/wp-content/uploads/2021/04/The-Solution-15.png)
The Solution
We present a novel 64Cu(II) based radiotracer that is incorporated in the copper cycle.
![](https://birad.biz/wp-content/uploads/2021/04/The-Commercial-Benefit-14.png)
The Commercial Benefit
Our product is a new 64Cu based radiotracer for hypoxia, based on molecular level understanding of the cellular transfer mechanism, rate, stability, and oxidation/reduction behavior. The novelty of this work is that it uses basic and fundamental knowledge on the cellular copper cycle, and generates a new compound that competes with the normal copper cycle, and its transfer mechanism is known and tracked in detail.
In a nutshell, our cutting-edge innovation is significantly superior to any other current radiotracers for hypoxia as:
- Its uptake ratio by the cell is high
- It is highly sensitive to the oxidation environment
![](https://birad.biz/wp-content/uploads/2021/04/Market-Potential-17.png)
Market Potential
The global medical imaging devices market is expected to generate revenue of $46.65 billion by 2023, growing at a CAGR of 5.47% during the forecast period. The introduction of innovative systems such as fusion imaging enabled CT/PET devices will contribute to the development of the medical imaging market during the forecast period.
PET-CT Scanner Device Market accounted for $1,454 million in 2016 and is estimated to reach $2,108 million by 2023, growing at a CAGR of 5% during the analysis period. There is a high prevalence of diseases worldwide, hence an increase in the need of diagnosis.
![](https://birad.biz/wp-content/uploads/2021/04/Target-Marktets.png)
Target Markets/Industries
- PET Imaging Manufacturers
- PET Imaging Distributors/Traders/Wholesalers
- PET Imaging Subcomponent Manufacturer
- Industry Association
- Downstream Vendors
![](https://birad.biz/wp-content/uploads/2021/04/Intellectual-Property-14.png)
Intellectual Property
Patent application pending (PCT/IL2018/051211)
![](https://birad.biz/wp-content/uploads/2021/04/Primary-Inventor.png)
Team: Primary Inventor
Prof. Sharon Ruthstein
- Prof. Ruthstein graduated with Honors her master's studies in the Chemistry Department at Weizmann Institute of Science, Rehovot, Israel.
- Prof. Sharon Ruthstein achieved her Ph.D. with Honors under the supervision of Prof. Daniella Goldfarb.
- After graduating from the Weizmann Institute in 2008, Prof. Ruthstein became an EMBO Postdoctoral Fellow at the University of Pittsburgh, where she worked under the supervision of Prof. Sunil Saxene
- Prof. Ruthstein joined the Department of Chemistry at Bar Ilan University in October 2011.
- Her research is aiming to exploit biological pathways in human and bacteria cells, which involve metal ions, using pulsed Electron Paramagnetic Resonance Spectroscopy (EPR).
![](https://birad.biz/wp-content/uploads/2021/04/Future-Research-15.png)
Future Research
Hypoxia is not only characteristic in solid tumors, but can also be found in plaques of α-synuclein, and αβ amyloids hence can diagnose Alzheimer's and Parkinson's diseases as well. We set our sights on these challenging directions.
![](https://birad.biz/wp-content/uploads/2021/04/The-Opportunity-15.png)
The Opportunity
We are looking for investors that are interested in license-translational sponsored research